78. Hypopituitarism Clinical trials / Disease details
Clinical trials : 494 / Drugs : 385 - (DrugBank : 49) / Drug target genes : 44 - Drug target pathways : 100
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02782208 (ClinicalTrials.gov) | February 10, 2016 | 18/5/2016 | Lipolytic Effects of GH in Hypopituitary Patients in Vivo | Lipolytic Effects of GH in Hypopituitary Patients in Vivo: Molecular Mechanisms and Temporal Patterns. | Hypopituitarism;Insulin Resistance;Endocrine System Diseases;Glucose Metabolism Disorders;Metabolic Diseases;Pituitary Diseases;Brain Diseases | Drug: Acipimox;Drug: Placebo;Drug: GH substitution;Other: GH pause | University of Aarhus | NULL | Completed | 18 Years | 70 Years | Male | 9 | N/A | Denmark |